In conclusion, although this study is limited by the analysis of only two patients, it provides a piece of knowledge about the dynamics of FLT3-TKD AML, showing that the presence of alterations in NRAS and/or KIT genes could predict resistance to gilteritinib. This evidence concerns the gene FLT3 and acute myeloid leukemia.